Application of Circulating Tumor Cell (CTC) PD-L1 Detection in the Evaluation of Therapeutic Efficacy in Advanced NSCLC: A Retrospective Study

被引：0
|
作者：
Deng, Y. [1 ]
Huang, Y. [2 ]
Cai, S. [1 ]
Yu, Z. [1 ]
Guo, X. [1 ]
机构：
[1] Shenzhen Canc Hosp, Shenzhen, Peoples R China
[2] Cell Shenzhen, Shenzhen, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
NSCLC; circulating tumor cell; immunotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.11A.11
引用
收藏
页码：S600 / S600
页数：1
相关论文
共 50 条
  • [21] PD-L1 blockade efficacy relies on host cell PD-L1
    Brownell, I.
    Udey, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : 1000 - 1000
  • [22] PD-L1 Expression is Related to Tumor Staging in NSCLC
    Wang, Hangjun
    Agulnik, Jason
    Kasymjanova, Goulnar
    Wang, Anna Y.
    Cohen, Victor
    Small, David
    Pepe, Carmela
    Sakr, Lama
    Fiset, Pierre O.
    Auger, Manon
    Camilleri-Broet, Sophie
    Alameldin, Mona
    Chong, George
    van Kempen, Leon
    Spatz, Alan
    MODERN PATHOLOGY, 2018, 31 : 755 - 755
  • [23] Association of PD-L1 expression with efficacy of alectinib in advanced NSCLC patients with ALK fusion
    Pan, Yingying
    Liu, Xinyu
    Zhang, Wei
    Wang, Wanying
    Wang, Haowei
    Luo, Libo
    Jia, Keyi
    Shao, Chuchu
    Mao, Shiqi
    Qiu, Tianyu
    Ni, Jun
    Yu, Jia
    Wang, Lei
    Chen, Bin
    Xiong, Anwen
    Gao, Guanghui
    Chen, Xiaoxia
    Wu, Fengying
    Zhou, Caicun
    Wu, Chunyan
    Ren, Shengxiang
    LUNG CANCER, 2023, 181
  • [24] PD-L1 Expression is Related to Tumor Staging in NSCLC
    Wang, Hangjun
    Agulnik, Jason
    Kasymjanova, Goulnar
    Wang, Anna Y.
    Cohen, Victor
    Small, David
    Pepe, Carmela
    Sakr, Lama
    Fiset, Pierre O.
    Auger, Manon
    Camilleri-Broet, Sophie
    Alameldin, Mona
    Chong, George
    van Kempen, Leon
    Spatz, Alan
    LABORATORY INVESTIGATION, 2018, 98 : 755 - 755
  • [25] Efficacy of Anti-PD-1/PD-L1 Monoclonal Antibody Treatment of Advanced NSCLC on Density and Distribution of Tumor Infiltrating T Cells
    Wang, Y.
    Wo, Y.
    Xue, X.
    Xue, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S333 - S333
  • [26] Circulating tumor cell (CTC) PD-L1 and interferon regulatory factor-1 (IRF-1) expression as biomarkers of anti-PD-(L)1 response.
    Kennedy, Laura
    Ramirez, Arturo B.
    U'Ren, Lance
    Sun, Yao
    Durenberger, Grace
    Chow, Laura Quan Man
    Grivas, Petros
    Gadi, Vijayakrishna K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] PD-L1 Expression on Cytological Imprints and Circulating Tumor Cells versus Standardized Immunohistochemistry in NSCLC
    Abdo, M.
    Belloum, Y.
    Heigener, D.
    Welker, L.
    Schmidt, M.
    Heuer-Olewinski, N.
    Elmas, H.
    Perner, S.
    Wikman, H.
    Pantel, K.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S559 - S560
  • [28] Circulating levels of PD-L1 and tumor metabolism correlate to patients outcome in surgically resected NSCLC
    Castello, Angelo
    Grizzi, Fabio
    Qehajaj, Dorina
    Toschi, Luca
    Rossi, Sabrina
    Pistillo, Daniela
    Lopci, Egesta
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [29] Sequential tracking of PD-L1 expression on circulating tumor cells in NSCLC patients treated with nivolumab
    Akamatsu, Hiroaki
    Koh, Yasuhiro
    Mori, Keita
    Kanai, Kuninobu
    Hayata, Atsushi
    Tokudome, Nahomi
    Higuchi, Masayuki
    Kanbara, Hlsashige
    Akamatsu, Keiichiro
    Nakanishi, Masanori
    Ueda, Hiroki
    Yamamoto, Nobuyuki
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [30] Noninvasive detection of PD-L1 on circulating tumor cells in patient blood samples
    Skibinski, David A. G.
    FUTURE ONCOLOGY, 2018, 14 (13) : 1237 - 1240
12345